Our comprehensive post-conference report from ASCO 2024 offers detailed insights into the latest clinical trials and treatment developments in Non-Small Cell Lung Cancer (NSCLC) and

Metabolism is altered in tumor cells and numerous inhibitors that target these metabolic pathways are currently being developed as treatments. There is growing evidence to

Surmounting all the challenges, 1st cell therapy approval in solid tumors is anticipated by 2022. The spectacular success of cell therapies observed in heme tumors